Hematologic diseases
Conditions
Interventions
Itrizole oral solution, 20ml at 11AM or Itrizole injection, 200mg at 11-12AM single daily dosing, are administered for ITCZ. Sandimmun injection , 20ml at 11AM or Itrizole injection, 200mg at 11-12AM
Sponsors
Cellular transplantation biology, Graduate School of Medical Science, Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meets all of 3 criteria as follows; 1. Patients with hematologic disease who will be treated with allogeneic hematopoietic stem cell transplantation (HSCT) and scheduled to be given CyA or TAC. 2. Patients who are treated, or who are planned to treat with ITCZ. 3. Written informed consent are obtained.
Exclusion criteria
Exclusion criteria: Patients who meets one (or more) of each criteria as follows; 1. AST/ALT &#8805;5.0 x Upper Limit of Normal(ULN) 2. Bilirubin &#8805;2 mg/dl 3. Hypersensitivity for ITCZ 4. Glomerular filtration rate <30 ml/min 5. Use of contraindicated drug to ITCZ 6. Be disqualified by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Create a calculating formula to predict the blood level of CyA or TAC and concentration-to-dose (C/D) ratio combined with ITCZ administration | — |
Countries
Japan
Contacts
Public ContactISHIYAMA, Ken
Graduate School of Medical Science, Kanazawa University Cellular transplantation biology
Outcome results
None listed